Carisma updates pipeline: CT-1119 Phase 1 start H1 2025, liver fibrosis IND in 2026

Carisma Therapeutics Inc.

CT-1119 (mesothelin-targeted CAR-Monocyte) Phase 1 trial with tislelizumab in solid tumors expected to start H1 2025.
Phase 1 trial to enroll up to 12 patients in China; initial safety/efficacy data anticipated Q4 2025.
Liver fibrosis program: preclinical in 2025 to enable regulatory submission in 2026, followed by Phase 1 in 2026.
Corporate presentation updated on company website with these pipeline milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.